KARYOPHARM THERAPEUTICS INCKPTI
ASignal's systematic analysis rates KPTI as Bearish.
Reflects the latest available analysis · analyzed Oct 1, 2026
The case on KPTI
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- RSI near oversold level (31.98) suggests potential downside exhaustion
- MACD histogram is positive and expanding, indicating weakening bearish momentum
- Gross margin exceptionally high at 99.06%, indicating strong pricing power or minimal COGS
- Price significantly below Bollinger Bands middle and upper bands, suggesting potential mean reversion
- Negative price momentum (-0.318) and trading below both SMA20 and SMA50
- Declining revenue (YoY growth -11.9%) and deeply negative operating cash flow
- High negative profit margin (-153.28%) and negative ROA (-47.61%)
- Elevated debt levels ($328.53M) relative to cash ($65.11M) and small market cap
- Current ratio (0.79x) and quick ratio (0.71x) indicate weak short-term liquidity
- Negative enterprise value to EBITDA (-3.54x) and forward P/E (-0.43x) reflect unprofitability
See the full verdict on KPTI
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes KPTI
Most investors never get a second opinion, let alone several. ASignal runs KPTI past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.